Zinc–Arginine–Ascorbic Acid for Local 5-Alpha-Reductase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for androgenetic alopecia, such as Finasteride, have significant side effects and there is a need for a local treatment that effectively inhibits the 5-alpha reductase type II enzyme without these drawbacks.
Innovation Solution
A formulation combining zinc gluconates, arginine gluconates, and ascorbic acid is used to inhibit the 5-alpha reductase type II enzyme and increase SOX9 protein gene expression, providing a local treatment for androgenetic alopecia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Finasteride is used to inhibit 5-alpha reductase type II, then hair loss due to androgenetic alopecia is effectively prevented, but significant side effects occur including erectile dysfunction, gynecomastia, memory loss, and depression
Solution Approach 1:
The patent introduces zinc gluconate and arginine gluconate as intermediary substances that can inhibit 5-alpha reductase type II enzyme activity. These intermediaries provide an alternative mechanism to Finasteride, achieving the desired therapeutic effect (inhibition of DHT production) while avoiding the harmful side effects associated with Finasteride use. The combination of zinc gluconate, arginine gluconate, and ascorbic acid serves as a mediator that accomplishes the same biological function without the toxicological profile of conventional treatments.
2Reliability
If Finasteride is used systemically, then androgenetic alopecia is treated, but the treatment affects the entire body causing systemic side effects
Solution Approach 1:
The patent applies local quality by formulating zinc gluconate and arginine gluconate in a topical composition for localized application to the scalp. This approach concentrates the therapeutic action at the site of androgenetic alopecia (the scalp and hair follicles) while avoiding systemic distribution throughout the body. The local application ensures that the 5-alpha reductase inhibition occurs primarily at the target site rather than systemically, thereby eliminating whole-body side effects while maintaining local therapeutic effectiveness.
3Object-affected harmful factors
If zinc and arginine gluconates are used alone, then some inhibitory activity against 5-alpha reductase is achieved, but the effectiveness is not comparable to Finasteride
Solution Approach 1:
The patent merges zinc gluconate and arginine gluconate with ascorbic acid to create a synergistic combination. While zinc gluconate and arginine gluconate individually exhibit some inhibitory activity against 5-alpha reductase, their combination with ascorbic acid enhances the overall effectiveness to levels comparable with or exceeding Finasteride. This merging of multiple substances creates a synergistic effect where the combined therapy achieves superior inhibitory activity while maintaining the advantage of reduced side effects.
Solution Approach 2:
The patent employs a composite material approach by combining zinc gluconate, arginine gluconate, and ascorbic acid into a single therapeutic formulation. This composite composition leverages the complementary properties of each component: zinc gluconate and arginine gluconate provide 5-alpha reductase inhibition, while ascorbic acid contributes additional beneficial effects and enhances stability. The composite material achieves high therapeutic effectiveness through the combined action of its components, matching Finasteride's efficacy without its adverse effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination effectively inhibits the 5-alpha reductase type II enzyme and increases SOX9 protein expression, comparable to Finasteride, but without the side effects, offering a stable and effective treatment for androgenetic alopecia.
Implementation Method 1
The transformation of testosterone into di-hydro-testosterone occurs locally, in the hair follicle itself and in the attached sebaceous gland, through the intervention of a specific enzyme called 5-alpha reductase type II. Several formulations have been tested in the past to locally inhibit the enzyme 5-alpha reductase type II... It should be noted that zinc and arginine gluconates have already been attributed a certain inhibitory activity against the enzyme 5-alpha reductase
Implementation Method 2
increased gene expression of the SOX9 protein by hair follicle cells. This particular effect, completely unexpected and independent of the former, can lead (according to available scientific data) to a stimulation of the dermal papilla of the hair follicle
Implementation Method 3
This particular effect, completely unexpected and independent of the former, can lead (according to availablescientific data) to a stimulation of the dermal papilla of the hair follicle and to a further contrasting action of hair miniaturization, typical of androgenetic alopecia
Data Source
Figure 1
Figure 2
AI summary
The present invention relates to a remedy against androgenetic alopecia, consisting of a combination or formulation comprising zinc and arginine gluconates combined with ascorbic acid.